[144] LIGAND PHARMACEUTICALS INC SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Ligand Pharmaceuticals, Inc. (LGND) regarding proposed and recent sales of common stock. The filer reports a proposed sale of 467 shares through UBS Financial Services (Eleven Madison Avenue, New York) with an aggregate market value of $82,509.56 and an approximate sale date of 10/01/2025. The filing shows the securities were acquired on 06/09/2023 from the issuer and that payment was completed on that date. The filer also disclosed sales in the past three months by John Kozarich totaling 1,868 shares on 07/10/2025, 08/01/2025, and 09/02/2025, with reported gross proceeds of $116,750.00, $61,614.49, and $75,746.26, respectively. The filing includes the filer’s certification that they are not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale filings covering small share amounts relative to outstanding shares; appears informational rather than material.

The Form 144 discloses a planned sale of 467 shares and three recent sales totaling 1,868 shares by an individual identified as John Kozarich. The aggregate market value of the planned sale is $82,509.56 and the issuer's outstanding shares are listed as 19,596,560, indicating the transactions represent a de minimis portion of the float. The securities were acquired 06/09/2023 from the issuer. There is no mention of any material corporate developments, earnings data, or change in control. From a trading-impact perspective, these disclosures fulfill Rule 144 notice requirements and are unlikely to be material to LGND’s valuation given the small relative size.

Compliance / Corporate Governance Expert

TL;DR: Filing meets procedural requirements for Rule 144 notices; includes necessary acquisition and prior-sales details and the seller's certification.

The document provides the essential elements for a Rule 144 notice: identification of the securities, broker name and address, number of shares to be sold, acquisition date and nature, and recent sales history with gross proceeds. The signature/representation language is present stating lack of undisclosed material adverse information and reminding of legal penalties for misstatements. No indications of reliance on a 10b5-1 plan are provided. As such, the filing appears compliant and routine from a disclosure and governance standpoint.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	467	82509.56	19596560	10/01/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/09/2023	Various	Issuer			467	06/09/2023	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Kozarich 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121	Common	07/10/2025	934	116750.00
John Kozarich 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121	Common	08/01/2025	467	61614.49
John Kozarich 3911 Sorrentino Valley Blvd. Suite 110 San Diego CA 92121	Common	09/02/2025	467	75746.26

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for LGND disclose about the planned sale?

The Form 144 discloses a proposed sale of 467 common shares through UBS Financial Services with an aggregate market value of $82,509.56 and an approximate sale date of 10/01/2025.

Who sold shares of LGND in the past three months and how many?

John Kozarich sold a total of 1,868 common shares on 07/10/2025 (934 shares), 08/01/2025 (467 shares), and 09/02/2025 (467 shares).

When were the securities to be sold originally acquired?

The securities were acquired on 06/09/2023 from the issuer, with the filing showing an acquisition amount of 467 shares.

What broker is handling the proposed sale?

The broker listed is UBS Financial Services, Inc. at Eleven Madison Avenue, 4th Floor, New York, NY 10010.

Does the filing state the number of outstanding shares for the issuer?

Yes. The filing lists 19,596,560 shares outstanding for the issuer.